<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The antiviral compound <z:chebi fb="1" ids="10110">azidothymidine</z:chebi> (<z:chebi fb="39" ids="10110">AZT</z:chebi>), alone or in combination with other agents, induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in early-passage, Epstein-Barr virus-positive Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (EBV+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) lines and has clinical activity in EBV+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We report here a mechanism of <z:chebi fb="39" ids="10110">AZT</z:chebi>'s antitumor activity </plain></SENT>
<SENT sid="2" pm="."><plain>The nuclei of these cells contain activated nuclear factor-kappaB (NF-kappaB) subunits p50, c-Rel, RelB, and p52, but not p65 </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment of primary EBV+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines with <z:chebi fb="39" ids="10110">AZT</z:chebi> inhibited NF-kappaB within 1 to 2 hours </plain></SENT>
<SENT sid="4" pm="."><plain>This was followed by up-regulation of EBV gene expression including <z:mp ids='MP_0001799'>viral</z:mp> <z:chebi fb="0" ids="17748">thymidine</z:chebi> kinase (vTK) and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>Subclones of EBV+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells that demonstrated activated p65 were resistant to <z:chebi fb="39" ids="10110">AZT</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>In EBV+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e>, <z:chebi fb="39" ids="10110">AZT</z:chebi> but not <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> (GCV) was highly phosphorylated to its monophosphate form (<z:chebi fb="39" ids="10110">AZT</z:chebi>-MP) </plain></SENT>
<SENT sid="7" pm="."><plain>Phosphorylation, as well as <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, was markedly enhanced in the presence of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="39" ids="10110">AZT</z:chebi> inhibits NF-kappaB and up-regulates EBV gene expression in primary EBV+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="39" ids="10110">AZT</z:chebi> with <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> may represent an inexpensive, targeted regimen for endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>